Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?

The arginine methyltransferase PRMT5 has been increasingly associated with cancer development. Here we describe our recent findings that PRMT5 is a critical regulator of breast cancer stem cell survival via the epigenetic regulation of FOXP1. Consequently, PRMT5 inhibitors could potentially eradicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Kelly, Davies, Clare C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964458/
https://www.ncbi.nlm.nih.gov/pubmed/29876520
http://dx.doi.org/10.1080/23723556.2018.1441628
_version_ 1783325183894880256
author Chiang, Kelly
Davies, Clare C.
author_facet Chiang, Kelly
Davies, Clare C.
author_sort Chiang, Kelly
collection PubMed
description The arginine methyltransferase PRMT5 has been increasingly associated with cancer development. Here we describe our recent findings that PRMT5 is a critical regulator of breast cancer stem cell survival via the epigenetic regulation of FOXP1. Consequently, PRMT5 inhibitors could potentially eradicate cancer stem cells thereby preventing tumour relapse.
format Online
Article
Text
id pubmed-5964458
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-59644582018-06-04 Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities? Chiang, Kelly Davies, Clare C. Mol Cell Oncol Author's Views The arginine methyltransferase PRMT5 has been increasingly associated with cancer development. Here we describe our recent findings that PRMT5 is a critical regulator of breast cancer stem cell survival via the epigenetic regulation of FOXP1. Consequently, PRMT5 inhibitors could potentially eradicate cancer stem cells thereby preventing tumour relapse. Taylor & Francis 2018-03-07 /pmc/articles/PMC5964458/ /pubmed/29876520 http://dx.doi.org/10.1080/23723556.2018.1441628 Text en © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author's Views
Chiang, Kelly
Davies, Clare C.
Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
title Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
title_full Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
title_fullStr Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
title_full_unstemmed Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
title_short Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
title_sort linking prmt5 to breast cancer stem cells: new therapeutic opportunities?
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964458/
https://www.ncbi.nlm.nih.gov/pubmed/29876520
http://dx.doi.org/10.1080/23723556.2018.1441628
work_keys_str_mv AT chiangkelly linkingprmt5tobreastcancerstemcellsnewtherapeuticopportunities
AT daviesclarec linkingprmt5tobreastcancerstemcellsnewtherapeuticopportunities

Ejemplares similares